Results 21 to 30 of about 19,854 (197)
JCI Insight, 2022 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
Alexander Merleev +19 more
doaj +1 more source
Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians
Acta Medica Bulgarica, 2023 The aim of this study was to investigate the potential association of rs11206510 in PCSK9 gene with coronary artery disease (CAD) and myocardial infarction (MI) in Bulgarians.
Tzveova R. +7 more
doaj +1 more source
Arteriosclerosis, Thrombosis, and Vascular Biology, 2004 Many of the most important breakthroughs in science do not come from hypothesis-driven experiments. Apart from serendipity, genetics is perhaps our best route to discoveries that elude our intuition. Genetics establishes a relationship between a gene and a phenotype, but does not necessarily provide mechanistic information. The emerging story of PCSK9 (
openaire +2 more sources
Renal Failure, 2020 Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria.
Huaying Shen +5 more
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus +5 more
doaj +1 more source
PCSK9 Association With Lipoprotein(a) [PDF]
Circulation Research, 2016 Rationale: Lipoprotein(a) [Lp(a)] is a highly atherogenic low-density lipoprotein–like particle characterized by the presence of apoprotein(a) [apo(a)] bound to apolipoprotein B. Proprotein convertase subtilisin/kexin type 9 (PCSK9) selectively binds low-density lipoprotein; we hypothesized that it ...
Hagai, Tavori +11 more
openaire +2 more sources
Revue medicale suisse, 2017 Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta +7 more
openaire +3 more sources
Cell, 2016 Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
openaire +2 more sources
Circulation Research, 2014 Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has attracted a lot of attention from the scientific community and pharmaceutical companies. Secreted into the plasma by the liver, the proteinase K–like serine protease PCSK9 binds the low-density lipoprotein (LDL) receptor at the surface of hepatocytes, thereby ...
Nabil G, Seidah +3 more
openaire +2 more sources
Frontiers in Genetics, 2014 Estimates from large scale genome sequencing studies indicate that each human carries up to 20 genetic variants that are predicted to results in loss of function (LOF) of protein-coding genes.
Patrick eSleiman +5 more
doaj +1 more source